KyungDong Pharm home
Prescription Medicines

Durocan Tab. 0.5mg

Product Category
Treatment for benign prostatic hyperplasia and male pattern hair loss
Active Ingredients
Dutasteride
Appearance
Yellow oblong film-coated tablets
Reimbursement Code
648104670
View Regulatory Information on the MFDS Portal ↗
1. Ingredient content
1 tablet
- Active ingredients:
Dutasteride (in-house specification) ----- 0.5mg
- Additives: Calcium silicate, microcrystalline cellulose, butylhydroxytoluene, magnesium stearate, Opadry yellow (03B62323), colloidal silicon oxide, crospovidone, polyoxyl 35, castor oil, propylene glycol monocaprylate, hydroxypropyl cellulose, D-mannitol.

2. Effectiveness
Treatment of benign prostatic hyperplasia:
Improved symptoms of benign prostatic hyperplasia, reduced risk of acute urinary retention, and reduced need for surgery related to benign prostatic hyperplasia.
Treatment of androgenetic alopecia in adult men (18 to 50 years of age)

3. Dosage and dosage
The recommended dosage of this drug is 1 tablet (0.5 mg) once a day. This medicine should be swallowed whole without chewing or breaking.
This medicine can be taken without regard to meals. There is no need to adjust the dose of this drug in patients with renal impairment or elderly patients. Because there are no data on the administration of this drug to patients with hepatic impairment, the recommended dosage of this drug in patients with hepatic impairment has not been established.

4. Precautions for use
1. Do not administer to the following patients.
1) Women
2) Children under 18 years of age
3) Patients with hypersensitivity to this drug, other components of this drug, or other 5α-reductase inhibitors


2. Administer with caution to the following patients.
1) Adult male planning to become pregnant (when using this drug to treat male pattern hair loss, it may affect reproductive function, so administer with caution under the doctor's judgment)
2) Patients with large urinary retention or severe reduction in urinary flow
In these patients, administration of 5α-reductase inhibitors may not be advisable, and urinary retention should be carefully monitored.
3) Patients with liver impairment
The effect of hepatic impairment on the pharmacokinetics of this drug has not been studied. Because this drug is extensively metabolized and has a half-life of approximately 3 to 5 weeks, this drug should be administered with caution to patients with liver function abnormalities.
4) Concurrent administration with a strong CYP3A4 inhibitor
Although this drug is extensively metabolized, no studies have been conducted on drug interactions related to metabolism and the effects of strong CYP3A4 inhibitors have not been tested. Due to the potential for drug interactions, caution should be exercised when administering this drug to patients chronically taking strong CYP3A4 enzyme inhibitors (e.g. ritonavir).

3. Adverse reactions
1) Most adverse reactions were mild or moderate, and generally recovered during treatment in both the this drug and placebo groups. The most frequent adverse reactions leading to discontinuation of the study drug in both treatment groups were related to the reproductive system.

2) Adverse reactions observed in clinical trials
① Adverse reactions that occurred when dutasteride was administered alone in clinical trials for benign prostatic hyperplasia
In three placebo-controlled phase 3 clinical trials, more than 4,300 male subjects with benign prostatic hyperplasia were randomly assigned to receive placebo or 0.5 mg of this drug. 2,167 people were administered this drug, of which 1,772 were administered for 1 year and 1,510 for 2 years. The subjects' ages ranged from 47 to 94 years old (average 66 years old), and more than 90% were white. During the two-year treatment period, 376 people (9% of each test group) withdrew from the trial due to adverse reactions, most of which were related to the reproductive system. Cases in which the study drug was discontinued due to an adverse reaction judged by the researcher to be possibly attributable to the test drug occurred in 4% of subjects administered this drug and 3% of subjects administered placebo. As shown below, adverse reactions (adverse reactions that occurred with a frequency of more than 1%) that the researchers judged to be related to this drug were reported more frequently when administering this drug compared to placebo in three phase 3 placebo-controlled clinical trials.
Adverse reactions related to this drug that occurred with a frequency of more than 1%
- Refer to the table in the manual -
② Adverse reactions that occurred when dutasteride was administered alone in clinical trials for male pattern hair loss
This drug was studied for the treatment of male pattern hair loss in two 6-month placebo-controlled phase 3 clinical trials and one phase 2 clinical trial. In these clinical trials, adverse reactions that investigators judged to be related to this drug (at a frequency of 2% or more) were listed below and were reported more frequently with this drug compared to placebo.
- Refer to the table in the manual -
③ Adverse reactions that occurred when coadministering dutasteride and tamsulosin in clinical trials for benign prostatic hyperplasia
In the 4-year CombAT (Combination of Avodart and Tamsulosin) trial to compare dutasteride 0.5 mg and tamsulosin 0.4 mg administered alone or in combination once a day, adverse reactions (adverse reactions that occurred with a cumulative frequency of 1% or more) that researchers judged to be related to dutasteride were reported as follows.
- Refer to the table in the manual -
● Heart failure: In the CombAT clinical trial, after 4 years of treatment, the incidence of complex heart failure in the combination treatment group (12/1,610; 0.7%) was higher than that of the tamsulosin alone group (2/1,623; 0.1%) and the tamsulosin alone group (9/1,611; 0.6%). Complex heart failure was also investigated in a separate 4-year placebo-controlled clinical trial evaluating this drug in men at risk for prostate cancer. The incidence of complicated heart failure in subjects receiving placebo was 0.4% (15/4,126), while the incidence in subjects receiving this drug was 0.6% (26/4,105). Most of the subjects with heart failure in both trials had comorbidities associated with an increased risk of heart failure. Therefore, the clinical significance of numerical imbalance in heart failure is unknown. No imbalance in the overall frequency of cardiovascular adverse events was observed in the two trials.
3) Long-term administration
① Reproductive system and breast disorders: In three major placebo-controlled benign prostatic hyperplasia clinical trials of this drug, each over a period of 4 years, there was no evidence of an increase in the incidence of drug-related sexual dysfunction (erectile dysfunction, decreased libido, ejaculation disorder) or breast disorders with increasing treatment period. Among these three clinical trials, one case of breast cancer occurred in the dutasteride group and one case occurred in the placebo group. In the 4-year CombAT clinical trial and the 4-year REDUCE clinical trial, no breast cancer was reported in any group. The relationship between long-term administration of this drug and the development of male breast neoplasms is currently unknown.
② High-grade prostate cancer: The REDUCE clinical trial was a randomized, double-blind, placebo-controlled clinical trial that enrolled 8,231 men aged 50 to 75 years with serum PSA levels between 2.5 ng/mL and 10.0 ng/mL and a negative prostate biopsy within the previous 6 months. Subjects were randomly assigned to receive placebo (N=4,126) or 0.5 mg of this drug (N=4,105) once daily for up to 4 years. The average age was 63 years old, and 91% were Caucasian. Subjects underwent scheduled prostate biopsies at the second and fourth years of treatment as specified in the protocol or biopsies to determine the cause at an unscheduled time point, at the discretion of the clinician. There was a higher incidence of Gleason grade 8-10 prostate cancer in men receiving this drug (1.0%) compared to men receiving placebo (0.5%). In a 7-year placebo-controlled clinical trial of another 5α-reductase inhibitor (finasteride 5 mg, Proscar), similar results were observed for Gleason grade 8-10 prostate cancer (finasteride 1.8% vs. placebo 1.1%). Clinical benefit has not been proven in patients with prostate cancer receiving this drug.
4) Post-marketing data
Adverse reactions were organized by institution and frequency. The frequencies are: very common (≥1/10), common (≥1/100 to <1/10), sometimes (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000). These adverse reactions may differ from the actual frequency because they also include adverse reactions reported voluntarily from a population of unknown size.
Adverse reactions reported after marketing of this drug are as follows.
① Immune system: Very rare allergic reactions including rash, itching, hives, local swelling, severe skin reactions, angioedema, etc.
② Mental system: Depressed mood very rarely
③ Skin and subcutaneous tissue: Rarely alopecia (mainly body hair loss), hirsutism
④ Reproductive system and breast: Very rarely, testicular pain and testicular swelling
⑤ New tissue: male breast cancer
5) Domestic post-marketing survey
① Results of a post-marketing use outcome survey conducted on 3,870 patients with benign prostatic hyperplasia over a period of 6 years (April 23, 2004 to April 22, 2010) for re-examination in Korea.
- The occurrence rate of adverse events was reported to be 3.8% (146 people/3,870 people, 198 cases) regardless of causal relationship. Among these, the incidence of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 3.4% (131 people/3,870 people, 171 cases), erectile dysfunction 1.9% (72 people/3,870 people, 75 cases), decreased libido 1.3% (49 people/3,870 people, 49 cases), and ejaculation disorder 0.8% (29 people/3,870 people, 49 cases). 29 cases), indigestion 0.1% (5 people/3,870 people, 5 cases), gynecomastia 0.1% (5 people/3,870 people, 5 cases), insomnia 0.1% (2 people/3,870 people, 2 cases), abdominal pain, diarrhea, solar plexus discomfort, allergy, fever, and nasal congestion 0.03% each (1 person/3,870 people, 1 case) was reported. The serious adverse event incidence rate was 0.1% (5 people/3,870 people, 5 cases) regardless of causal relationship, and thrombotic stroke, lung cancer, pulmonary embolism, pneumonia, and diarrhea were reported.
The incidence of unexpected adverse events was 0.5% (20 people/3,870 people, 28 cases) regardless of causal relationship, including 3 cases of dry mouth, 2 cases each of constipation, abdominal pain, insomnia, and diarrhea, convulsions, orofacial abnormalities, vomiting, colonic polyps, solar plexus discomfort, asthenia, nasal congestion, deep vein thrombosis, fever, chills, gastroesophageal reflux, hemorrhoids, pain, pneumonia, One case each of pulmonary embolism, lung cancer, and thrombotic stroke was reported. Among these, the occurrence rate of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 0.16% (6 people/3,870 people, 7 cases), with 2 cases of insomnia and 1 case each of nasal congestion, abdominal pain, diarrhea, solar plexus discomfort, and fever.
As a result of a subgroup analysis of 76 long-term users who had taken this drug for more than 2 years, the adverse event rate was reported to be 7.89% (6 people/76 people, 10 cases) regardless of causal relationship. Among these, the rate of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 5.3% (4 people/76 people, 5 cases), with 2 cases of decreased libido and 1 case each of erectile dysfunction, indigestion, and ejaculation disorder reported. One case each of pulmonary embolism and pneumonia was reported as a serious adverse event, regardless of causal relationship, and one case each of pulmonary embolism, orofacial dyskinesia, xerostomia, and pneumonia was reported as an unexpected adverse event, regardless of causal relationship.
② The results of a post-marketing use survey conducted on 712 adult males (18-41 years old) who received this drug for the treatment of male pattern hair loss over a period of 4 years (July 23, 2009 - July 22, 2013) for re-examination in Korea.
- The adverse event rate was reported to be 15.4% (110/712 people, 138 cases) regardless of causal relationship. Among these, the incidence of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 9.3% (66/712 people, 80 cases), with 9 cases of decreased libido, 8 cases of indigestion, 7 cases of erectile dysfunction, 5 cases each of fatigue and increased SGPT, and 4 cases each of rash and sexual dysfunction.
The occurrence rate of serious adverse events was 0.6% (4/712 people, 5 cases) regardless of causal relationship. Two cases of pharyngitis, one case each of appendicitis, fracture, and viral infection were reported, but they did not correspond to serious adverse drug reactions.
The incidence of unexpected adverse events was 8.1% (58/712 people, 69 cases) regardless of causal relationship: 6 cases of pharyngitis, 5 cases of increased SGPT, 4 cases each of acne and fungal dermatitis, 3 cases each of seborrhea, skin disease, and increased SGOT, 2 cases each of folliculitis, eczema, appendicitis, fatty liver, chest pain, palpitations, warts, contact dermatitis, Dry skin, peptic ulcer, gastritis, gastroenteritis, drowsiness, bilirubinemia, upper respiratory tract infection, fracture, unspecified abrasion, surgical intervention, laceration, hyperuricemia, hypertriglyceridemia, weight gain, paresthesia, decreased testosterone, skeletal pain, plantar fasciitis, viral infection, bacterial infection, purpura, epistaxis, blepharitis, benign laryngeal neoplasm, nephrolithiasis, dysgeusia, telangiectasia. One case was reported, of which the adverse drug reaction rate for which a causal relationship with this drug cannot be ruled out was 3.5% (25/712 people, 29 cases), with 5 cases of increased SGPT, 3 cases of increased SGOT, 2 cases each of acne, skin disease, folliculitis, palpitations, fungal dermatitis, seborrhea, warts, drowsiness, bilirubinemia, pharyngitis, surgical intervention, hypertriglyceridemia, weight gain, One case each of paresthesia, decreased testosterone, nosebleeds, and dysgeusia were reported in that order.
③ As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of the re-examination, the following are newly identified adverse events that were statistically significantly more reported for this drug compared to the adverse events reported for all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
Skin and appendage disorders: acne, dry skin
Visual impairment: visual impairment
Liver and biliary tract diseases: fatty liver
Metabolic and Nutritional Disorders: Thirst
Urinary system diseases: urinary abnormalities, hematuria
Reproductive dysfunction (male): Semen abnormalities
Neoplasm: Gastric Carcinoma

4. General precautions
1) Lower ureter symptoms of benign prostatic hyperplasia can be an indicator of other urinary diseases, including prostate cancer. Patients should be evaluated for other urinary tract diseases before administering this drug.
2) Blood donation
To prevent the drug from being administered to a pregnant woman during a blood transfusion, patients taking this drug should not donate blood until at least 6 months have passed since the last time they took this drug.
3) Prostate-specific antigen (PSA)
① A digital rectal examination, as well as other evaluations for prostate cancer, should be performed on patients with benign prostatic hyperplasia before starting treatment with this drug and regularly after treatment.
② PSA serum concentration is an important factor in the screening stage for prostate cancer diagnosis.
③ This drug reduces total serum PSA concentration by approximately 40% after 3 months of administration and by approximately 50% after 6 months of administration.
Therefore, in order to interpret the serum PSA value in men taking this drug, the initial value of the PSA concentration must be reset 3 to 6 months after administration, and this new initial value must be used to evaluate potential changes in the PSA value related to cancer.
④ For patients taking this drug who need prostate cancer screening, a new PSA baseline value must be established 6 months after taking this drug. It is recommended to monitor PSA values ​​regularly thereafter. A confirmed increase in PSA from the nadir level during treatment with this drug may be a sign of the presence of prostate cancer or refractoriness to treatment with this drug and should be carefully evaluated, even if such values ​​are within the normal range for men not taking 5α-reductase inhibitors. In interpreting PSA values ​​for patients taking this drug, previous PSA values ​​should be referenced for comparison. Administration of this drug does not preclude the use of PSA as an adjunct to the diagnosis of prostate cancer after a new PSA baseline level has been established.
⑤ The total serum concentration of PSA returns to the initial value within 6 months after discontinuation of this drug.
⑥ The ratio of free PSA value to total PSA value remains constant while taking this drug. If a physician chooses the percentage of free PSA to diagnose prostate cancer in male patients taking this drug, no correction to this value is necessary.
4) Prostate cancer
In a four-year clinical trial (REDUCE trial) of 8,231 men aged 50 to 75 years with a baseline PSA level of 2.5 ng/mL to 10.0 ng/mL and a previous negative biopsy for prostate cancer, 1,517 men were diagnosed with prostate cancer. There was a higher incidence of Gleason grade 8 to 10 prostate cancer in the lysine-treated group (n=29, 1.0%) compared to the placebo group (n=19, 0.5%). There was no increase in the incidence of Gleason grade 5 to 6 or 7 to 10 prostate cancer. The causal relationship between this drug and high-grade prostate cancer has not been proven, and the clinical significance of the numerical imbalance is unknown. However, because this drug may increase the risk of developing high-grade prostate cancer, men taking this drug should be periodically evaluated for their risk of prostate cancer, including a PSA test.
In a 2-year extended follow-up study of subjects in the dutasteride REDUCE clinical trial, similar results were observed for the development of new prostate cancer (dutasteride [n=14, 1.2%], placebo [n=7, 0.7%]), with no new cases of Gleason grade 8 to 10 prostate cancer among these patients.
5) Breast cancer was reported in men who received dutasteride during clinical trials and post-marketing surveillance. In epidemiological studies, no increase in the risk of developing male breast cancer was observed following administration of 5α-reductase inhibitors. Physicians should instruct patients to promptly report any changes in breast tissue, such as lumps or nipple discharge. The causal relationship between long-term administration of dutasteride and the development of male breast cancer is not clear.
6) Effects on fertility
When 0.5 mg/day of this drug was administered to healthy subjects aged 18 to 52 years (dutasteride n = 27, placebo n = 23) for 52 weeks, the effect of this drug on semen characteristics was evaluated during the 52 weeks of administration and 24 weeks of follow-up after the end of administration. At week 52, the average rate of decrease from initial values ​​in total sperm count, semen volume, and sperm motility in the drug-treated group was 23%, 26%, and 18%, respectively, when adjusted for the average decrease rate in the placebo-treated group. Sperm concentration and sperm morphology were not affected. After a 24-week follow-up period, the average percent change in total sperm count in the treatment group was 23% lower than the initial value. At each test point, the average values ​​of all semen-related evaluation variables were within the normal range, and there were no clinically significant changes (preliminarily defined as 30%). However, in two subjects in the treatment group, the sperm count decreased by more than 90% from the initial value at 52 weeks and partially recovered at 24 weeks after the end of treatment. The clinical significance of the effect of this drug on the characteristics of semen, which is the reproductive capacity of each patient, has not yet been determined.
7) Information for patients
① Pregnant women or women with the potential to become pregnant should not handle this drug due to its absorption potential and potential risk to the developing male fetus due to absorption.
② Patients should be informed that the amount of ejaculation may decrease in some patients while taking this drug. Reduced ejaculate volume does not appear to interfere with normal sexual function. In clinical trials, erectile dysfunction and decreased sexual desire occurred in a small number of subjects receiving this drug or placebo, and investigators believed they were related to the test drug.
③ To prevent this drug from being administered to pregnant women during blood transfusion, patients taking this drug should not donate blood until at least 6 months have passed since the last time they took this drug.
8) Based on the pharmacodynamic and pharmacokinetic properties of this drug, this drug is not expected to affect the ability to drive or operate machinery.
9) Heart failure
In two 4-year clinical trials, the frequency of heart failure (adverse reactions mainly reported as heart failure and congestive heart failure) was higher in patients receiving dutasteride and an α-blocker (mainly tamsulosin) in combination than in patients not receiving the combination. The incidence of heart failure in these two trials was low (≤1%) and differed between the two trials. No imbalance in the overall frequency of cardiovascular adverse events was observed in either trial. A causal relationship between dutasteride (either alone or in combination with α-blockers) and heart failure has not been established.

5. Interaction
1) In in vitro drug metabolism studies, this drug was metabolized by human CYP3A4, so the blood concentration of this drug may increase in patients taking CYP3A4 inhibitors. Therefore, caution should be exercised when administering this drug to patients chronically taking strong CYP3A4 inhibitors.
2) This drug did not inhibit the in vitro metabolism of substrates of major human CYP450 isoenzymes (CYP1A2, CYP2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP2B6, and CYP2D6) at a concentration of 1000 ng/mL, which is 25 times higher than the steady-state serum concentration of humans. Additionally, this drug did not induce CYP P450 isoenzymes CYP1A, CYP2B, or CYP3A in in vivo tests in dogs and rats.
3) Calcium channel antagonist: As a result of pharmacodynamic (PK) analysis of phase 2 clinical trial data, a decrease in clearance of this drug was confirmed when the CYP3A4 inhibitor verapamil (-37%, n = 6) and diltiazem (-44%, n = 5) were co-administered. Conversely, when this drug was co-administered with amlodipine (+7%, n = 4), a calcium channel antagonist but not a CYP3A4 inhibitor, no decrease in clearance of this drug was observed.
When co-administered with CYP3A4 inhibitors (e.g. verapamil and diltiazem), the decreased clearance and subsequent increased exposure of this drug are not considered clinically significant due to the wide safety margin of this drug (up to 10 times the recommended dose has been administered to patients for up to 6 months), so dose adjustments are not recommended.
4) α-Adrenergic blockers: In a cross-over study on healthy volunteers, when this drug was co-administered with tamsulosin or terazosin for 2 weeks, it did not affect the steady-state pharmacokinetics or pharmacodynamics of these α-adrenergic blockers. The rate of change in 5α-dihydrotestosterone (DHT) concentration during co-administration was similar to that when this drug was administered alone.
In clinical trials, this drug and tamsulosin were administered together for 24 weeks, and then this drug and tamsulosin were administered together for 12 weeks, or this drug was administered alone. After the 12-week treatment period, there were no excessively severe adverse reactions or discontinuation of the test drug due to adverse reactions in the combination treatment group compared to the single-administration group.
5) In in vitro tests, this drug does not replace warfarin, diazepam, acenocoumarol, phenprocoumon, or phenytoin at the plasma protein binding site, or these model compounds do not replace this drug.
6) Warfarin: When 0.5 mg/day of this drug was co-administered with warfarin to 23 healthy subjects for 3 weeks, it did not change the steady-state pharmacokinetics of S- or R-warfarin isomers, nor did it change the effect of warfarin on prothrombin time.
7) Digoxin: When 0.5 mg/day of this drug was co-administered with digoxin to 20 healthy subjects for 3 weeks, the steady-state pharmacokinetics of digoxin were not changed.
8) Cholestyramine: When 12 g of cholestyramine was administered to 12 normal volunteers one hour after a single dose of 5 mg of this drug, it did not affect the relative bioavailability of this drug.
9) Other combination therapy: Although interaction tests with other drugs were not specifically conducted, approximately 90% of subjects who received this drug in phase 3 clinical trials were taking other drugs concurrently. In clinical trials, when this drug was co-administered with antihyperlipidemic agents, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic blockers, calcium channel blockers, corticosteroids, diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), phospho-diesterase Type V inhibitors, and quinolone antibiotics, there were no clinically significant negative interactions due to co-administration with this drug.

6. Administration to pregnant women, lactating women, children, and the elderly
1) Pregnant women
This drug is contraindicated in women. This drug was not tested in women because nonclinical study results suggested that external genital development may be impaired in male fetuses conceived by exposed women due to inhibition of circulating dihydrotestosterone (DHT) levels.
2) Administration to nursing mothers
This drug is contraindicated in women. It is not known whether this drug passes into human breast milk.
3) Administration to children
This drug is contraindicated in children under 18 years of age. Safety and efficacy in children under 18 years of age have not been established.
4) Administration to elderly people
- Benign prostatic hyperplasia: Of the 2,167 subjects administered this drug in three clinical trials for benign prostatic hyperplasia, 60% were over 65 years of age and 15% were over 75 years of age. No differences in safety or efficacy were observed between these subjects and younger subjects. In other clinical experiences, no differences in response were reported between elderly and young patients.
- Male pattern baldness in adult men: Clinical trials for the treatment of male pattern baldness were conducted on adult male patients under the age of 50. There are no efficacy data for patients with male pattern hair loss over 50 years of age.

7. Treatment in case of overdose
In volunteer studies, doses of this drug up to 40 mg/day (80 times the usual dose) were administered once daily for 7 days without any particular concerns about safety. In the clinical trial, 60 subjects were administered 5 mg of this drug per day (10 times the therapeutic dose) for 6 months, and there were no additional adverse reactions compared to when 0.5 mg was administered. There is no specific antidote for this drug, so when symptoms of overdose are suspected, appropriate supportive therapy should be administered considering the long half-life of this drug.

8. Storage and handling precautions
1) Keep out of reach of children.
2) Removing medicines from their original container and storing them in another container may cause accidents due to misuse of medicines or cause a decrease in the quality of medicines, so keep them in their original containers.

9. Pharmaceutical equivalence test information
A 2×2 cross-over study was conducted between the test drug Durocan tablets 0.5 mg (Dutasteride) [KyungDong Pharm Co., Ltd.] and the reference drug Avodart soft capsule 0.5 mg (Dutasteride) [Glaxo Smith Kline Co., Ltd.]. As a result, 1 tablet of the test drug and 1 capsule of the reference drug were administered orally once on an empty stomach to healthy adults, and Dutasteride in the blood of 28 people was measured. When comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
* Table: refer to manual

10. Other
1) Laboratory tests
① Effect on PSA: In patients administered this drug, the prostate volume decreases, so the PSA value generally decreases. In about half of the subjects, the PSA value decreased by 20% within 1 month of administration. Six months after administration, the PSA value stabilized to a new initial value of approximately 50% of the value before administration. Results from subjects treated with this drug for up to 2 years showed a sustained decrease in PSA values ​​of up to 50%. Therefore, the initial PSA value must be reset 3 to 6 months after administering this drug.
② Hormone levels: In healthy volunteers, the levels of globulin-binding sex hormones, estradiol, luteinizing hormone, follicle-stimulating hormone, thyroxine (free T4), and dehydroepiandrosterone did not change clinically significantly when 0.5 mg/day (n = 26) of this drug was administered for 52 weeks compared to placebo (n = 23). There was a statistically significant increase in total testosterone (97.1ng/dL, p<0.003) at week 8 and thyroid-stimulating hormone (TSH) (0.4mcIU/mL, p<0.05) at week 52 compared to placebo. The median rate of change from the initial value within the treatment group was 17.9% at 8 weeks for testosterone and 12.4% at 52 weeks for TSH. The average values ​​of testosterone and TSH in subjects for whom data were available at each test recovered to initial levels during the 24-week follow-up period after discontinuation of treatment. In a large-scale phase 3 clinical trial in which this drug was administered to patients with benign prostatic hyperplasia, the median increase in luteinizing hormone was 12% at 6 months and 19% at 12 and 24 months.
2) Central nervous system toxicity
When this drug was repeatedly administered orally to rats and dogs, non-specific, reversible, and central nervous system-mediated toxicity was observed in some experimental animals, but no relevant histopathological changes were observed when exposed to 425 and 315 times the clinical dose, respectively.
3) Carcinogenicity
In a 2-year carcinogenicity study in B6C3F1 mice, males were administered doses of 3, 35, 250, and 500 mg/kg/day, and females were administered doses of 3, 35, and 250 mg/kg/day. An increase in the incidence of benign hepatocellular adenoma was confirmed only in females administered 250 mg/kg/day (290 times the expected clinical exposure when administered at 0.5 mg per day). Two of the three major metabolites in humans were identified in mice. It is not known whether exposure to these metabolites in mice is lower than in humans.
In a 2-year carcinogenicity study in Han Wistar rats, doses of 1.5, 7.5, and 53 mg/kg/day in males and 0.8, 6.3, and 15 mg/kg/day in females resulted in an increase in Leydig cell adenomas in the testes at 53 mg/kg/day (135 times the estimated clinical exposure). An increased incidence of Leydig cell hyperplasia was observed in males at doses of 7.5 mg/kg/day (52 times the estimated clinical exposure) and 53 mg/kg/day. A positive correlation between the proliferation changes of Leydig cells and the increase in circulating luteinizing hormone levels was demonstrated by 5α-reductase administration, which was consistent with the effect on the hypothalamic-pituitary-testicular axis after 5α-reductase inhibition. At the carcinogenic dose in rats, rat luteinizing hormone levels increased by 167%. In this study, the carcinogenicity of major metabolites in humans was tested when exposed to approximately 1 to 3 times the clinical exposure.
In carcinogenicity tests on rats, benign stromal cell tumors increased at high doses (158 times the clinical exposure). However, the endocrine mechanisms thought to be involved in mesangial cell hypertrophy and adenomas in rats are not relevant to humans. Carcinogenicity studies in mice showed no clinically relevant effects on tumor profile.
4) Hereditary
This drug did not show genotoxicity in various in vitro and in vivo tests.
As a result of testing the genotoxicity of this drug through bacterial mutagenicity test (Ames test), chromosomal aberration test in CHO cells, and micronucleus test in rats, the possibility of genotoxicity of this drug was not shown.
The two major metabolites in humans were also not mutagenic in the Ames test or modified Ames test.
5) Reproductive and developmental toxicity
When 0.05, 10, 50, and 500 mg/kg/day (0.1 to 110 times the estimated clinical exposure of the maternal drug) was administered to sexually mature male rats for up to 31 weeks, reproductive performance decreased in a dose- and time-dependent manner, sperm count in the epididymis decreased but sperm concentration did not decrease (50, 500 mg/kg/day), and weight of the epididymis, prostate, and seminal vesicles decreased. Microscopic changes were observed in the male reproductive organs. In all test drug administration groups, reproductive function recovered at 6 weeks of recovery, and sperm count became normal at the end of 14 weeks of recovery. 5α-reductase-related changes included cytoplasmic vacuolization of epididymal tubular epithelial cells and decreased cytoplasmic content of epithelial cells, consistent with decreased secretory activity in the prostate and seminal vesicles. In the low-dose group, microscopic changes no longer appeared at 14 weeks of recovery, and there was partial recovery in the remaining dose groups. When males administered 10, 50, or 500 mg/kg/day for 29 to 30 weeks were mated with females not administered the test drug, low concentrations (0.6 to 17 ng/mL) of this drug were detected in the serum of the females. This drug caused a reversible decrease in fertility in male rats, which is consistent with its pharmacological activity in inhibiting 5α-reductase in accessory reproductive organs. This effect is not considered clinically significant because there was no effect on sperm development, concentration, or motility.
In an embryo-fetal development study in female rats, oral administration of 0.05, 2.5, 12.5, and 30 mg/kg/day of this drug resulted in feminization of male fetuses (reduced anogenital distance) and feminization of male neonates (nipple development, hypospadias, and preputial gland swelling) at all doses (estimated to be 0.07 to 111 times the clinical exposure to males). An increased incidence of skeletal muscle deformities associated with delayed ossification associated with weight loss was observed at doses of 12.5 and 30 mg/kg/day (56 to 111 times the estimated clinical exposure). Additionally, at doses above 2.5 mg/kg/day (2 to 10 times the estimated clinical exposure of the maternal drug in humans), litter size was reduced and embryo resorption and feminization of male fetuses increased. Fetal weight also decreased at doses above 0.05 mg/kg/day (less than 0.02 times the human exposure dose).
In a perinatal orally administered test to rats, this drug was administered at doses of 0.05, 2.5, 12.5, and 30 mg/kg/day. Feminization of the genitalia (e.g., decreased anogenital distance, increased hypospadias, and nipple development) in F1 generation male neonates was evident at doses above 2.5 mg/kg/day (14 to 90 times the estimated clinical exposure in men). At a dose of 0.05 mg/kg/day (0.05 times the estimated clinical exposure), there was a small but statistically significant decrease in anogenital distance as evidence of feminization. When administered at 2.5 to 30 mg/kg/day, the gestation period in female mothers increased, the time to vaginal opening in female neonates, and the seminal vesicle weight in male neonates decreased. The effect on neonatal stimulation response was observed at doses higher than 12.5 mg/kg/day. At the dose of 30mg/kg/day, the number of stillbirths increased.
Feminization of male fetuses is an expected physiological result of inhibition of conversion of testosterone to DHT by administration of 5α-reductase inhibitors. These results are similar to those observed in male newborns genetically deficient in 5α-reductase.
In an embryo-fetal study in rabbits, doses of 30, 100, and 200 mg/kg (28 to 93 times the expected clinical exposure in men) were administered on days 7 to 29 of conception, which corresponds to the final period of external genitalia development. When the papillary papillae of the fetuses were evaluated histologically, evidence for feminization of male fetuses was found at all doses. A second embryo-fetal study in rabbits at doses of 0.05, 0.4, 3.0, and 30 mg/kg/day (0.3 to 53 times the estimated clinical exposure) also showed evidence of genital feminization in male fetuses at all doses. It is not known whether major human metabolites are present in rabbits or rhesus monkeys. However, when this drug was administered intravenously to pregnant monkeys at doses up to 2010 ng/animal/day during embryo-fetal development, no harmful maternal or fetal toxicity was observed. In an embryo-fetal development test (12/group) administered intravenously to rhesus monkeys, no adverse reactions occurred in the development of male external genitalia when doses of 400, 780, 1325, and 2010 ng/day were administered on days 20 to 100 of conception. Decreased fetal adrenal gland weight, decreased fetal prostate weight, and increased fetal ovarian and testicular weight were observed in monkeys administered the highest dose. The maximum concentration of this drug detected in the semen of a man who received repeated oral administration for 12 months was 14ng/mL. Assuming that this drug is 100% absorbed by a 50 kg woman through 5 mL of semen per day, the maximum exposure to this drug is 1.4 ng/kg. In an embryo-fetal development test administered intravenously to rhesus monkeys, there was no effect on male fetal development even at a concentration of 260ng/kg (corresponding to 186 times the maximum exposure to women through human semen) when converted to ng/kg. Additionally, because this drug has a very high binding rate (> 96%) to proteins in human semen, vaginal absorption may be reduced.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/box (10 tablets/PTP×3)

7. Period of use
36 months from date of manufacture